David Jürgens

David is a passionate scientist, COO, and co-founder of RNhale, focused on innovating practices in inhalation-based medicine. He began his career with preclinical work on inhalable mRNA therapeutics before pursuing a PhD at the Chair of Drug Delivery at LMU Munich. At LMU, he co-founded RNhale, aiming to develop the next generation of inhalable drugs. David is working on pioneering RNA-based treatments for severe asthma using advanced Nano-Embedded in Microparticle (NEM) technology.